Relanab® 500 Tablet: Each film coated tablet contains Nabumetone USP 500 mg.
Relanab® 750 Tablet: Each film coated tablet contains Nabumetone USP 750 mg.
Indications: Relanab® (Nabumetone) is indicated for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.
Dosage & administration: Relanab® (Nabumetone) is contraindicated in patients with known hypersensitivity to Nabumetone or its excipients. Relanab® should not be given to patients who have experienced asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. It is contraindicated for the treatment of pre-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Use in Pregnancy & Lactation: Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. Nabumetone should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. The effects of Nabumetone on labor and delivery in pregnant women are unknown.
Drug Interactions: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
Storage: Keep out of reach of children. Store in a dry place, below 25° C temperature and protected from light.
Relanab (Nabumetone) is an NSAID dry mouth, gastritis, stomatitis, vomiting, dizziness, NSAID used to treat osteoarthritic and rheumatoid arthritic headache, fatigue, increased sweating, insomnia, RR pain. nervousness, somnolence, pruritus, rash, tinnitus, AS
Mode of action:
Relanab (Nabumetone) is a non-se- edema. a FA CIS AT ar lective prostaglandin G/H synthase inhibitor that acts on Use in Pregnancy & Lactation: Pregnancy Category 2 (COX-1 COX-2) FA both prostaglandin G/H synthase 1 and 2 (COX-1 and C. There are no adequate, well-controlled studies in Grid
-2). Prostaglandin G/H synthase catalyzes the pregnant women. Nabumetone should be used in.
conversion of arachidonic acid to prostaglandin G2 and pregnancy only if the potential benefit justifies the fer 2 prostaglandin G2 to prostaglandin H2. Prostaglandin potential risk to the fetus. It is not known whether this WS HA LD 2 : H2 is the precursor to a number of prostaglandins drug is excreted in human milk. The effects of TU, SISA, AR, ROS ALA AR involved in fever, pain, swelling, inflammation, and Nabumetone on labor and delivery in pregnant women AA platelet aggregation. The analgesic, antipyretic and are unknown. NSAID Ta anti-inflammatory effects of NSAIDs occur as a result of f decreased prostaglandin synthesis Precautions: Administration of an NSAID results in a dose-dependent decrease in prostaglandin synthesis NSAIDs
Pharmacokinetics:
After oral administration, approxi- and, secondarily, in a reduction of renal blood flow, AA, FACS AAC mately 80% of a dose of Nabumetone is found in the which may precipitate overt renal decompensation. urine, indicating that Nabumetone is well absorbed from Patients at greatest risk of this reaction are those with NSAIDs the gastrointestinal tract. After absorption, it undergoes impaired renal function, heart failure, liver dysfunction, aT AT wes those taking diuretics, and the elderly. Discontinuation (6MNA) A mately 35% of dose by fo the eit Vo ,000- pretreatment state. converted to and 50% is converted into unidenti- AES GAIT CHAT fied metabolites. Nabumetone is excreted in the urine. Drug interactions: Reports suggest that NSAIDs may TNS
Relanab (Nabumetone) is indicated for failure, respiratory depression, and coma may occur, the relief of signs and sympt f ost thriti d but are rare. Anaphylactic reactions have been reported ymptoms of osteoarthritis an afe with therapeutic ingestion of NSAIDs, and may occur rheumatoid arthritis. following an overdose. AACR \.
The recommended starting Wet core 3090 fat dose is 1,000 mg taken as a single dose with or without Storage: Keep out of reach of children. Store in a dry core food. Relanab (Nabumetone) can be given in either a place, below 25 C temperature and protected from light CREM CIOS 2000 single or twice-daily dose. Dosages greater than 2,000 Packaging: fra.
mg per day have not been studied. The lowest effective dose should be used for chronic treatment. Patients weighing under 50 kg may be less likely to require beyond 1,000 mg; therefore, after observing the response to initial therapy, the dose should be adjusted to meet individual patients requirements.
Relanab 500 mg: Each box contains 10x3 s tablets in Alu-Alu blister pack. Relanab 750 mg: Each box contains 6x3 s tablets in Alu-Alu blister pack.
Fal Co WSL, SAY Fat
excipients.